DONALDSON Co INC acquired Solaris Biotechnology S.r.l. for approximately EUR 41 million / $45.7 million (net of cash acquired), a transaction completed in November 2021, structured as all cash.
Solaris Biotechnology S.r.l. operates in Life Sciences, is based in Headquartered in Porto Mantovano, Italy; U.S. operations in Berkeley, California. Solaris designs and manufactures bioprocessing equipment, including bioreactors, fermenters and tangential flow filtration systems for use in pharma, food and beverage, biotechnology and other life sciences markets. Headquartered in Porto Mantovano, Italy, with U.S. operations based in Berkeley, California.
Expands Donaldson's bioprocessing equipment offering and establishes a Life Sciences manufacturing base in Europe.
Life Sciences segment (initially reported within IFS / Industrial Products)
On November 22, 2021, the Company acquired Solaris, headquartered in Porto Mantovano, Italy, with U.S. operations based in Berkeley, California, for cash consideration of approximately EUR 41 million, or $45.7 million, net of cash acquired. Solaris designs and manufactures bioprocessing equipment, including bioreactors, fermenters and tangential flow filtration systems.Donaldson FY2022 10-K, Note 2 Acquisitions
Advisory firms were not disclosed for this transaction.